Harmony Biosciences Holdings (HRMY) Change in Account Payables (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Change in Account Payables data on file, last reported at $10.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 193.59% year-over-year to $10.9 million; the trailing twelve-month figure through Mar 2026 stood at $11.1 million (up 1114.94% YoY), and the FY2025 full-year result was $3.9 million, up 173.35% from the prior year.
• Change in Account Payables climbed to $10.9 million in Q1 2026, from -$8.6 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $10.9 million in Q1 2026 to a low of -$12.2 million in Q3 2024.
• A 5-year average of $1.2 million and a median of $2.6 million in 2023 frame the typical range for Change in Account Payables.
• Peak annual rise in Change in Account Payables reached 4021.48% in 2024, while the deepest fall reached 50529.17% in 2024.
• Tracing HRMY's Change in Account Payables over 5 years: stood at -$6.3 million in 2022, then soared by 198.93% to $6.2 million in 2023, then tumbled by 48.16% to $3.2 million in 2024, then slumped by 369.24% to -$8.6 million in 2025, then soared by 226.12% to $10.9 million in 2026.
• Business Quant data shows HRMY's Change in Account Payables at $10.9 million in Q1 2026, -$8.6 million in Q4 2025, and -$2.0 million in Q3 2025.